The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | 3-year DFS results from NICHE-2 of ipilimumab and nivolumab in dMMR colon cancer
Myriam Chalabi, MD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the NICHE-2 trial (NCT03026140) of ipilimumab and nivolumab prior to surgery in patients with locally advanced MMR-deficient (dMMR) colon cancer. A 100% 3-year disease-free survival (DFS) rate was observed with no recurrences. Circulating tumor DNA (ctDNA) monitoring showed significant ctDNA clearance pre-surgery, particularly in patients with a pathologic complete response. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
